AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

TheraVet SA Regulatory Filings 2021

Nov 9, 2021

4012_iss_2021-11-09_05aff3eb-cc5e-477b-9bd5-b823e9f45909.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

TheraVet announces the signing

of a research contract with Degroof Petercam

Gosselies (Wallonia, Belgium), November 9, 2021 – 7:30am CET – TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today, the signing of a research contract with Degroof Petercam.

Banque Degroof-Petercam will initiate coverage of the Company through its sponsored research program, and support the Company in investors networking with roadshows and conferences through its corporate access services.

About TheraVet SA

TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet's mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the US.

For more information, visit www.thera.vet

Contacts TheraVet Sabrina Ena Chief Operating Officer [email protected]

Julie Winand Chief Corporate Officer [email protected]

NewCap